– Results demonstrate robust therapeutic potential of proprietary drug combinations, validating the Company’s method of identifying and targeting core pathways to improve brain function – – EEG, ...
Mountain View, California Monday, February 16, 2026, 18:00 Hrs [IST] ...
– Compelling PAX-D results guided Alto’s acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto plans to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results